Key result
Phenotyping patients with HFpEF is important to increase the effectiveness of therapy, as treatments like beta-blockers or ivabradine may not be universally effective.
Why the study?
Pharmacotherapy that improves outcomes in chronic heart failure with preserved ejection fraction has not been developed despite its high prevalence.
Does heart rate reduction with beta-blockers or ivabradine improve outcomes in patients with HFpEF?
Does heart rate reduction with beta-blockers or ivabradine improve outcomes in patients with HFpEF?
Answers are grounded in this paper and cite their sources.
Phenotyping patients with HFpEF is important to increase the effectiveness of heart rate reduction therapies like beta-blockers and ivabradine.
Chronic heart failure with preserved ejection fraction (HFpEF) accounts for about 50% of cases of heart failure, but pharmacotherapy that improves its outcomes has not been developed. The proven principle of improving outcomes in patients with chronic heart failure with a reduced of left ventricular ejection fraction is the decrease in heart rate. The article discusses situations in which treatment with β-blockers is not effective or negatively affects outcomes. The results of own research and the EDIFY project, in which ivabradine was used in patients with HFpEF, were compared. The importance of phenotyping patients with HFpEF is stated to increase the effectiveness of their therapy.
No takes yet. Share an insight, caveat, or question.
Кanorskiy et al. (2018) conducted a review in Chronic heart failure with preserved ejection fraction (HFpEF). Beta-blockers and ivabradine was evaluated. Phenotyping patients with HFpEF is important to increase the effectiveness of therapy, as treatments like beta-blockers or ivabradine may not be universally effective.
Synapse has enriched 10 related papers. Consider them for comparative context: